Scarica l'app Stockscreener
15.90
0.69%
-0.13
Dopo l'orario di chiusura:
15.87
-0.03
-0.19%
Precedente Chiudi:
$16.03
Aprire:
$16.19
Volume 24 ore:
69,053
Relative Volume:
0.72
Capitalizzazione di mercato:
$211.16M
Reddito:
$116.26M
Utile/perdita netta:
$-11.08M
Rapporto P/E:
-20.08
EPS:
-0.7917
Flusso di cassa netto:
$1.04M
1 W Prestazione:
+8.82%
1M Prestazione:
+9.94%
6M Prestazione:
+61.79%
1 anno Prestazione:
+47.27%
Intervallo 1D:
$15.74
$16.49
Intervallo di 1 settimana:
$14.70
$16.49
Portata 52W:
$7.8701
$16.49
Anika Therapeutics Inc Stock (ANIK) Company Profile
Nome
Anika Therapeutics Inc
Settore
Telefono
(781) 457-9000
Indirizzo
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
15.87 | 213.29M | 116.26M | -11.08M | 1.04M | -0.7917 |
TAK
Takeda Pharmaceutical Co Adr
|
16.96 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.84 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.65 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.29 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
563.70 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | B. Riley Securities | Buy |
| 2024-11-01 | Reiterato | Barrington Research | Outperform |
| 2023-08-14 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Ripresa | Stephens | Equal-Weight |
| 2022-03-09 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Iniziato | Stephens | Overweight |
| 2021-07-16 | Iniziato | UBS | Neutral |
| 2020-12-16 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Aggiornamento | Sidoti | Neutral → Buy |
| 2020-01-10 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Iniziato | BWS Financial | Sell |
| 2019-09-24 | Reiterato | Barrington Research | Outperform |
| 2019-09-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Aggiornamento | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Downgrade | Sidoti | Buy → Neutral |
| 2018-07-27 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Reiterato | Barrington Research | Outperform |
| 2016-05-09 | Aggiornamento | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Anika Therapeutics Inc Borsa (ANIK) Ultime notizie
Price to book forward of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine - Traders Union
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell 2000 Defensive Index - marketscreener.com
Early MRI scans uncover hidden risks in rotator cuff repair, Integrity Implant System data show - Traders Union
Anika Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANIK) - TradingView
ANIK Forecast — Price Target — Prediction for 2027 - TradingView
Anika Therapeutics unveils Hyalofast cartilage repair scaffold using Hyaff hyaluronic acid technology - Traders Union
Behavioral Patterns of ANIK and Institutional Flows - Stock Traders Daily
Anika Shareholders Approve Directors and Expanded Incentive Plans - TipRanks
Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant - Stock Titan
Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares - Stock Titan
Anika Therapeutics (ANIK) director awarded 10,402 RSUs in stock grant - Stock Titan
[Form 4] Anika Therapeutics, Inc. Insider Trading Activity - Stock Titan
Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant - Stock Titan
Anika Therapeutics increases equity plan shares under amended omnibus and ESPP - TradingView
Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate - Stock Titan
Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biologics may shift outcomes in tendon injuries, Anika Therapeutics explores - Traders Union
Anika Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Anika Therapeutics Inc (ANIK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anika Therapeutics Inc (ANIK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Anika Therapeutics Inc (ANIK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Anika Therapeutics Inc (ANIK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Anika Therapeutics Inc (ANIK) Institutional Confidence - TradingKey
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anika Therapeutics introduces Cingal as only approved HA and corticosteroid combination for OA pain - Traders Union
(ANIK) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Anika Therapeutics (ANIK) Holds Steady Near Support Amid Low VolumeMonthly Profile - newsline.com
Anika Therapeutics Q1 2026 Earnings: Massive EPS Beat Fuels OptimismConsensus Forecast Report - newsline.com
Anika Therapeutics (ANIK) Edges Higher as Shares Test Key Resistance LevelsInside Day Breakout - newsline.com
Anika reports inducement grants - Medical Buyer
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Anika Therapeutics grants 3,360 RSUs to new employee as inducement under Nasdaq rules. - Pluang
New Anika hire receives 3,360 stock units as job inducement - Stock Titan
Anika (NASDAQ: ANIK) CEO exercises RSUs, withholds shares to cover tax - Stock Titan
Anika Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Griffin Stephen D. - Moomoo
Anika Therapeutics introduces proprietary Hyaff material for next generation regenerative applications - Traders Union
How (ANIK) Movements Inform Risk Allocation Models - Stock Traders Daily
Anika Therapeutics (ANIK) Holds Steady Near Support as Slight Decline PersistsIV Contraction - thelegaladvocate.com
Anika Therapeutics (ANIK) Hovers Near Support With Minimal Price MovementAndrews Pitchfork - dars.gov.et
ANIKAnika Therapeutics Inc Stock Price and Quote - Finviz
Anika Therapeutics (ANIK) Slides 1.6% Amidst Market Pressure – Key Levels to WatchOrder Block - The Legal Advocate
ANIK Stock Analysis: Anika Therapeutics Inc. gains 3.31 percent daily, trades at 14.98 dollar - Newser
Anika Therapeutics (ANIK) Holds Near Support After Slight DeclineIntraday Profile - newsline.com
ORIC Stock Heads Into Weekend as Cancer-Trial Deadline Approaches - Bez Kabli
Trading Systems Reacting to (ANIK) Volatility - Stock Traders Daily
Anika Therapeutics (ANIK) Q1 2026 Earnings: Surprise EPS Beat Amid Revenue UncertaintyAnnual Financial Report - newsline.com
ANIK Q1 2026 Earnings: Surprise Profit Swing as Anika Therapeutics Beats ExpectationsAnnual Earnings Summary - Newser
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anika Therapeutics Inc Azioni (ANIK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Griffin Stephen D. | President and CEO |
Apr 30 '26 |
Buy |
12.29 |
12,200 |
149,881 |
36,163 |
0.15%
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):